#1MERCK INVENTING FOR LIFE Merck Q3 2023 Earnings October 26, 2023#2Agenda Strategy and Business Update Rob Davis Chairman and Chief Executive Officer Business/Financial Results and Outlook Caroline Litchfield Chief Financial Officer Research Update Dr. Dean Li President, Merck Research Laboratories Question & Answer Session MERCK 2#3Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA This presentation of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2022 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov). MERCK 3#4MERCK INVENTING FOR LIFE Strategy and Business Update Rob Davis Chairman and Chief Executive Officer#5Delivered on our key strategic priorities in Q3 2023 < < > Advanced the pipeline to meet patient unmet need Executed on strategic business development to augment pipeline Achieved strong commercial and financial performance Created long-term value for patients and shareholders Daiichi-Sankyo & MERCK MERCK 5#6Strong Q3 sales performance and earnings growth¹ Q3 Worldwide Sales $16.0B +7% +8% ex-Exchange, ex-LAGEVRIO² Q3 Non-GAAP EPS3,4 Full Year Sales $59.3B +22% GUIDANCE RANGE $59.7B-$60.2B $48.7B +17% 2021 Full Year Non-GAAP EPS3 2022 2023 $2.13 +15% $5.37 $7.48 GUIDANCE RANGE $1.33 - $1.38 2021 2022 1. Results from continuing operations attributable to Merck & Co., Inc. 2. Excludes Lagevrio sales of $640 million in 3Q23 and $436 million in 3Q22. 3. Merck does not exclude expenses for upfront and milestone payments related to collaborations and licensing agreements, or charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. YTD 2023 non-GAAP results include an aggregate $11.6 billion or $4.52 per share of R&D expenses related to the Prometheus and Imago acquisitions and upfront payment for the license and collaboration agreement with Kelun-Biotech. Full year 2022 non-GAAP results include $690 million or $0.22 of such charges. Full year 2021 non-GAAP results include $1.7 billion or $0.65 of such charges. For 2023, guidance includes an additional $5.5 billion or $1.70 per share related to the collaboration with Daiichi Sankyo, and guidance does not assume any additional significant potential business development transactions. 4. GAAP EPS of $1.86. 2023 MERCK 6#7Advancing and enhancing our deep pipeline Oncology Highlights • KEYNOTE-671: Received FDA approval for KEYTRUDA for the neoadjuvant and adjuvant treatment of certain patients with resectable non-small cell lung cancer • ESMO: Compelling data presented across a wide range of molecules, tumor types and indications Cardiometabolic Highlights . • Sotatercept: FDA accepted for priority review the BLA for sotatercept for the treatment of adults with pulmonary arterial hypertension based on STELLAR ⚫ MK-0616: Started Phase 3 program for oral PCSK9 inhibitor candidate MERCK 7#8Continuing to deliver on our purpose for patients Pursuing transformative science to save and improve lives around the world MERCK 8#9MERCK INVENTING FOR LIFE Business/Financial Results and Outlook Caroline Litchfield Chief Financial Officer#10Strong underlying Q3 worldwide sales growth Merck WORLDWIDE SALES1,2 $16.0B +7% growth +6% ex-LAGEVRIO3 +8% ex-exchange, ex-LAGEVRIO3 Human Health $14.3B +10% growth +9% ex-LAGEVRIO3 +10% ex-exchange, ex-LAGEVRIO³ Animal Health $1.4B +2% growth +2% ex-exchange 1. Results attributable to Merck & Co., Inc. 2. Worldwide Sales includes Other Revenue. 3. Excludes Lagevrio sales of $640 million in 3Q23 and $436 million in 3Q22. MERCK 10#11Oncology: KEYTRUDA continues to drive exceptional growth • KEYTRUDA sales of $6.3B increased 17% year-over-year, driven by global uptake in earlier stage cancers and continued strong global demand from metastatic indications - In the U.S., growth of 14% reflects strong utilization across metastatic indications and earlier stage cancers, such as TNBC KEYTRUDA (pembrolizumab) Injection 100 mg - Ex-U.S., 22% increase driven by uptake in earlier stage cancers, including high-risk early- $5.4B +26% stage TNBC and adjuvant RCC, as well as increased demand in advanced RCC and certain types of H&N cancer $4.5B +21% Growth rates exclude the impact of foreign exchange. $6.3B +17% 3Q21 3Q22 3Q23 MERCK 11#12Oncology: Solid performance across broad portfolio Lynparza olaparib tablets 150 mg • Lynparza¹ sales grew 6% driven primarily by pricing in the U.S. and increased demand in Latin America • Lenvima² sales grew 30% driven by timing of shipments in China and increased demand in advanced RCC and endometrial cancer indications in the U.S. $246M +25% Growth rates exclude the impact of foreign exchange. 1. In collaboration with AstraZeneca 2. In collaboration with Eisai $284M +23% $299M +6% 3Q21 3Q22 3Q23 LENVIMA (lenvatinib) capsules and 10 mg 4 mg $188M +30% $202M $260M +30% +11% 3Q21 3Q22 3Q23 MERCK 12#13Vaccines: Robust growth driven by GARDASIL • GARDASIL sales of $2.6B increased 16% year-over-year driven by strong demand, particularly in China - In the U.S., sales decreased due to the GARDASIL. [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] GARDASIL.9 [Human Papillomavirus 9-valent Vaccine, Recombinant] timing of CDC purchases $2.3B +20% $2.6B +16% • Strong uptake of the pediatric indication of VAXNEUVANCE in the U.S. and $2.0B +63% launches in key European markets Growth rates exclude the impact of foreign exchange. 3Q21 3Q22 3Q23 MERCK 13#14Hospital: Contributions from key products bridion (sugammadex) 100 mg/mL Injection BRIDION sales of $424M were flat as greater share among neuromuscular blockade reversal agents in the U.S. was offset by the impact of generic entry primarily in Europe PREVYMIS sales grew 38% driven by continued strong global demand Growth rates exclude the impact of foreign exchange. $423M $369M +15% +22% $424M +0% 3Q21 3Q22 3Q23 0000000 $96M +22% PREVYMIS (letermovir) 240 mg, 480 mg tablets Injection 20 mg/mL $114M +29% $157M +38% 3Q21 3Q22 3Q23 MERCK 14#15Animal Health: Growth driven by livestock • Animal Health sales increased 2% to $1.4B - Livestock growth of 7% reflects price actions and increased demand for ruminant, poultry and swine products MERCK Animal Health - Companion Animal sales declined 4% due to a reduction in vet visits in the U.S., partially offset by pricing actions $1.4B +14% $1.4B +4% $1.4B +2% Growth rates exclude the impact of foreign exchange. 3Q21 3Q22 3Q23 MERCK 15#16Q3 2023 non-GAAP financial results summary¹ $ in billions, except EPS amounts Q3 2023 Q3 2022 Change Change Ex-FX Sales $16.0 $15.0 +7% +9% Non-GAAP Gross Margin 77.0% 77.0% -0.1pts +0.8pts Non-GAAP Operating $5.8 $6.0 -4% -3% Expenses Non-GAAP Tax Rate 15.0% 13.6% +1.4pts N/A Non-GAAP EPS2,3 $2.13 $1.85 +15% +22% 1. Merck is providing certain 2023 and 2022 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's results because management uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management's annual compensation is derived in part using a non-GAAP pre-tax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the earnings release. 2. Q3 2022 includes $690 million of R&D expense for collaborations and licensing agreements with Moderna, Orna and Orion, or $0.22 of negative impact to EPS. 3. Q3 2023 GAAP EPS of $1.86. MERCK 16#17Merck updated full-year 2023 guidance. Revenue Non-GAAP Gross Margin Rate Non-GAAP Prior Guidance $58.6B to $59.6B -1% to +1% (+1% to +3% ex-FX) Updated Guidance $59.7B to $60.2B +1% to +2% (+3% to +4% ex-FX) ~77.0% $34.0B to $34.6B ~77.0% $39.8B to $40.4B Operating Expenses¹ Other (Income) / Expense ~$100M of expense ~$200M of expense Tax Rate Shares Outstanding Non-GAAP EPS² ~30.5% to 31.5% ~39.0% to 40.0% ~2.55B $2.95 to $3.05 ~2.55B $1.33 to $1.38 Key Assumptions • Includes approximately $1.3B of LAGEVRIO revenue • Ex-LAGEVRIO, growth of 9% to 10% (11 to 12% ex-FX) Assumes ~2 ppt FX headwind • • Includes additional $5.5B related to upfront charge for the collaboration with Daiichi Sankyo as well as investment to advance the assets Includes updated FX expectations and higher net interest expense related to the Daiichi Sankyo collaboration Includes ~24.5 ppt impact related to business development activity Assumes modest share repurchase Includes $1.70 one-time charge for the Daiichi Sankyo collaboration and an additional $0.04 to advance the assets and finance the transaction Assumes 6 ppt FX headwind (additional $0.05 headwind) 1. Updated guidance includes an aggregate $17.1 billion of R&D expenses related to the Prometheus and Imago acquisitions, and upfront payments for the license and collaboration agreement with Kelun-Biotech and collaboration agreement with Daiichi Sankyo. Guidance does not assume any additional significant potential business development transactions. 2. Updated guidance includes $6.22 of one-time charges related to the Prometheus and Imago acquisitions and upfront payments to Kelun-Biotech and Daiichi Sankyo. MERCK 17#18Remain committed to balanced capital allocation strategy $ Billions¹ $2.6 Capital allocation order of priority $0.9 $1.9 $0.5 $0.1 After-Tax R&D CapEx Dividends Paid Business Development Share Repurchase 1. Reflects Q3 spend. (ex-divestitures) Continue to invest in our pipeline and business while augmenting our pipeline with value enhancing business development MERCK 18#19MERCK INVENTING FOR LIFE Research Update Dr. Dean Li President, Merck Research Laboratories#20Continuing to advance our oncology strategy Immuno-oncology Boost anti-tumor immune responses Precision Molecular Targeting Impact pathways that can drive cancer growth Tissue Targeting Increase cancer cell sensitivity with ADCs and immune-engagers MERCK 20#21..... Broadening and advancing our ADC presence U3-1402 (HER3-DXd) MK-2870 DS-7300 (I-DXd) DS-6000 (R-DXd) MK-1200 Collaborator Daiichi Sankyo Kelun Biotech Daiichi Sankyo Daiichi Sankyo Kelun Biotech 1 additional clinical asset Kelun Biotech Patritumab Generic Name deruxtecan Sacituzumab tirumotecan Ifinatamab deruxtecan Raludotatug deruxtecan Undisclosed Undisclosed Target HER3 TROP2 B7H3 CDH6 Claudin 18.2 Undisclosed Status Phase 31 Phase 3 Phase 2 Phase 1 Phase 1 Phase 1 Current Tumor Types² EGFRM NSCLC, Breast NSCLC, Breast ES-SCLC, Advanced Solid Tumors Ovarian Gl Tumors Undisclosed KEYNOTE-A39/ EV-3023 Data presented at ESMO from Phase 3 study evaluating KEYTRUDA in combination with enfortumab vedotin in 1L locally advanced or metastatic urothelial carcinoma 1. Planning to submit a biologics license application (BLA) in the U.S. by the end of March 2024 based on the Phase 2 HERTHENA-Lung01 data in EGFRm NSCLC that has progressed after EGFR TKI and platinum-based therapies 2. Shows tumor types currently being studied in various phases of development 3. Trial conducted in collaboration with Seagen and Astellas MERCK 21#22Sharing data from our earlier stage oncology program Lung • KEYNOTE-671: • . Presented positive overall survival data at ESMO from Phase 3 study ⚫ KEYTRUDA is the first and only anti-PD(L)-1 therapy to demonstrate statistically significant improvement in OS and EFS as perioperative treatment for resectable stage II, IIIA or IIIB NSCLC versus pre- operative chemotherapy • OS benefit generally consistent across majority of subgroups 6th KEYTRUDA indication for NSCLC to receive FDA approval Women's Cancers • Presented positive data at ESMO: ⚫ KEYNOTE-756 in patients with ER+ HER2-breast cancer • • KEYNOTE-522 in patients with high-risk early-stage TNBC KEYNOTE-A18 in patients with high-risk locally advanced cervical cancer . FDA granted priority review with target action date of January 20th Bladder • KEYNOTE-123: Announced Phase 3 trial evaluating KEYTRUDA for the adjuvant treatment of certain patients with localized muscle- invasive urothelial carcinoma and locally advanced urothelial carcinoma significantly improved disease-free survival MERCK 22#23Leveraging precision medicine to improve outcomes for patients WELIREG MK-10841 MK-3543 Presented data at ESMO from Phase 3 LITESPARK-005 study for treatment of adults with previously treated advanced RCC, which showed statistically significant and clinically meaningful improvement in progression-free survival vs. everolimus (standard of care) • FDA granted priority review with target action date of January 17th Proceeding with additional Phase 3 studies • Presented data at ESMO for oral KRAS inhibitor as monotherapy in solid tumors and in combination with KEYTRUDA in patients with metastatic NSCLC whose tumors harbored KRAS G12C mutations • Began enrolling patients in Phase 3 study evaluating bomedemstat (LSD1 inhibitor) in 2L essential thrombocythemia 1. In collaboration with Taiho and Astex MERCK 23#24Bringing new cancer treatments to patients around the world Europe • Granted approval for KEYNOTE-091 for adjuvant treatment of certain patients with NSCLC • Granted approval for KEYNOTE-811 for 1L treatment of patients with certain gastric or gastroesophageal junction adenocarcinoma Japan • Received approval for Lynparza in combination with abiraterone and prednisone for treatment of certain adult patients with BRCA-mutated metastatic castration-resistant prostate cancer based on Phase 3 PROpel study 1. In collaboration with AstraZeneca MERCK 24#25Significant advancements across our broader pipeline and portfolio Vaccines • V116: ⚫ STRIDE-3 data will be presented at World Vaccine Congress West Coast on November 28th • If approved, V116 would be the first pneumococcal conjugate vaccine designed to address serotypes responsible for the majority of adult invasive pneumococcal disease Immunology • MK-7240: . • Beginning to enroll patients in Phase 3 study for treatment of patients with ulcerative colitis Cardiometabolic Sotatercept: . . • Presented post-hoc analysis from STELLAR and interim analysis from SOTERIA, an open label extension study in PAH FDA granted priority review for Biologics License Application with target action date of March 26th ⚫ Completed submission to EMA in the European Union ⚫ MK-0616: . . Initiated Phase 3 CORALreef Lipids study in broad patient population with hypercholesterolemia • Initiated Phase 3 CORALreef HeFH study for patients with heterozygous familial hypercholesterolemia . Enrollment has begun for CORALreef Outcomes study measuring time to first occurrence of major atherosclerotic cardiovascular events in high risk patients MERCK 25#26MERCK INVENTING FOR LIFE Q&A Rob Davis Chairman & Chief Executive Officer Caroline Litchfield Chief Financial Officer Dr. Dean Li President, Merck Research Laboratories Peter Dannenbaum Vice President, Investor Relations#27Appendix MERCK 27#28Q3 2023 GAAP financial results summary $ in billions, EPS amounts Q3 2023 Q3 2022 Change Change Ex-FX Sales $16.0 $15.0 +7% +9% Operating Expenses $5.8 $6.9 -16% -16% Tax Rate 15.5% 9.2% +6.3pts N/A GAAP EPS $1.86 $1.28 +45% +55% MERCK 28#29Capital allocation: Trailing twelve months. Over the past 12 months $15 $12 $9 $10.1 $6 Billions is is in in $3 $0 Order of priority $13.1 $7.3 $4.0 After-Tax R&D CapEx Dividends Paid Business $1.0 Share Development1 Repurchase (ex-divestitures) Capital investments 2023 to 2027 ~$18B Over 5 years, including expanding manufacturing capacity for Oncology, Vaccines, and Animal Health. Includes >$10B in the U.S. 1. Includes payments reflected in operating cash flow Dollars per share Well positioned balance sheet with capacity to fund additional value-enhancing business development opportunities Commitment to the dividend $3.20 +6% $2.90 +6% +7% $2.92 $2.60 +11% $2.76 +15% $2.60 $2.30 $2.44 $2.00 +2% +2% +2% +2% +2% $2.20 $1.70 $1.76 $1.80 $1.84 $1.88 $1.92 $1.40 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023E MERCK 29#30Driving value for patients and shareholders by progressing our pipeline Key regulatory milestones since the last earnings call: • In the U.S.: 。 FDA accepted for priority review the SNDA for WELIREG for the treatment of patients with advanced RCC immune checkpoint and anti-angiogenic therapies based on LITESPARK-005 。 FDA accepted for priority review the sBLA for KEYTRUDA in combination with concurrent chemoradiotherapy for the treatment of patients with newly diagnosed high-risk locally advanced cervical cancer based on KN-A18 o Received FDA approval for KEYTRUDA in the perioperative setting for the treatment of certain patients with resectable NSCLC based on KN-671 。 FDA approved KEYTRUDA for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell cancer based on KN-017 and KN-913 。 FDA accepted for priority review the BLA for sotatercept for the treatment of patients with PAH based on STELLAR 。 FDA approved an expanded indication for ERVEBO for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older • In the EU: o Received EMA approval for KEYTRUDA in combination with trastuzumab and chemotherapy as 1L treatment in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma in PD-L1 positive patients based on KN-811 o Received EMA approval for KEYTRUDA in patients with adjuvant NSCLC based on KN-091 o Received positive CHMP opinion for KEYTRUDA in combination with chemotherapy for 1L treatment of certain patients with locally advanced unresectable or metastatic HER2- gastric or GEJ adenocarcinoma based on KN-859 o Received EMA approval for an expanded indication for ERVEBO for active immunization of individuals 12 months of age and older to protect against Ebola Virus Disease (EVD) caused by Zaire ebolavirus • In Japan: o Received approval of Lynparza¹ in certain patients with BRCA-mutated castration-resistant prostate cancer 。 Accepted for review the sJNDA for KEYTRUDA in the perioperative setting for the treatment of patients with resectable NSCLC based on KN-671 1. In collaboration with AstraZeneca 2. Trial conducted in collaboration with Seagen and Astellas 3. In collaboration with Eisai 4. In collaboration with Moderna 5. In collaboration with Kelun-Biotech 6. In collaboration with Taiho and Astex Key data & clinical advancements since the last earnings call: Presented data across broad oncology portfolio at ESMO, including for KEYTRUDA (KN-A392, KN-671, KN-A18, KN- 522, KN-756, KN-811), Lenvima³, Lynparza¹, WELIREG (LITESPARK-005), V940/mRNA-41574 (INT), MK- 2870/SKB2645 (TROP2 ADC) and MK-10846 (KRAS G12C) Announced Phase 3 KN-123 trial met one of its dual primary endpoints of disease-free survival for the adjuvant treatment of patients with localized muscle-invasive urothelial carcinoma and locally advanced urothelial carcinoma after surgery Presented new analyses from studies of sotatercept at ERS, including post-hoc analysis of right heart catheterization and echocardiography data from the STELLAR study and interim analysis of the Phase 3 SOTERIA open-label extension study Advanced broad pipeline, including: o Initiated Phase 3 clinical program for MK-0616, an oral PCSK9 inhibitor 。 Poised to initiate Phase 3 trials for V9404 in NSCLC, MK-28705 in NSCLC and MK-7240 in UC MERCK 30#31Broad and innovative pipeline to address significant unmet medical needs. Phase 2 Oncology Phase 3 KEYTRUDA (MK-3475) CSCC (EU) LENVIMA (MK-7902) Esophageal Gastric LYNPARZA (MK-7339) NSCLC SCLC MK-1026 (nemtabrutinib) WELIREG (MK-6482) Hematological Malignancies RCC (EU) MK-1308A (quavonlimab MK-7684A (vibostolimab Melanoma +pembrolizumab) NSCLC +pembrolizumab) TUKYSA (MK-7119) Breast CRC MK-3475A (pembrolizumab +hyaluronidase) NSCLC V940 Melanoma Under regulatory review Oncology KEYTRUDA (MK-3475) 2L HCC (US) LA Cervical (US) Resectable NSCLC (EU, JPN) 1L HER2- Gastric (US, EU, JPN) 1L Biliary (US, EU, JPN) WELIREG (MK-6482) Advanced RCC (US) General medicine Gefapixant (MK-7264) Cough (US) PREVYMIS (MK-8228) Prophylaxis of CMV in kidney transplant patients (EU) Cardiovascular MK-7962 (sotatercept) Pulmonary Arterial Hypertension (US) Oncology MK-0482 NSCLC MK-1308 (quavonlimab) NSCLC MK-1308A KEYTRUDA (MK-3475) MK-4830 Advanced Solid Tumors CRC WELIREG (MK-6482) Biliary MK-7684A (vibostolimab Prostate Esophageal Melanoma Certain VHL tumors (EU) +pembrolizumab) CRC Hepatocellular (EU) Biliary Mesothelioma MK-3543 NSCLC Endometrial Bladder Ovarian (bomedemstat) Ovarian Esophageal SCLC Breast Myeloproliferative RCC HCC Cervical (quavonlimab Disorders SCLC Pancreatic CRC +pembrolizumab) Rare Cancers Endometrial CRC MK-4280 MK-5684 SCLC (favezelimab) Esophageal Prostate TUKYSA (MK-7119) Gastric NSCLC Advanced Solid Tumors MK-2140 (zilovertamab HCC +pembrolizumab) MK-5890 (boserolimab) Bladder RCC vedotin) MK-4280A HNSCC NSCLC Bladder (favezelimab+pembroli Biliary SCLC Cervical Breast zumab) Ovarian Prostate Endometrial Gastric Bladder LYNPARZA (MK-7339) Gastric Hematological Malignancies cSCC Advanced Solid Tumors NSCLC NSCLC Esophageal Ovarian Melanoma LENVIMA (MK-7902) Pancreas RCC Biliary SCLC HNSCC MK-2870 Pancreas Neoplasm Malignant Vaccines V181 Dengue Virus Infectious diseases MK-8591B (islatravir+MK-8507)¹ HIV-1 Infection MK-8591D (islatravir+lenacapavir)² HIV-1 Infection Prostate SCLC Cardiovascular MK-2060 Thrombosis MK-5475 Pulmonary Arterial Hypertension MK-7962 (sotatercept) Pulmonary Hypertension due to Left Heart Disease 1On FDA clinical hold 2On FDA partial clinical hold for higher doses than those used in current clinical trials 3 Available in the US under EUA 4Development is co-funded by Royalty Pharma Note: Pipeline does not include the three DXd ADCs from the collaboration with Daiichi Sankyo General medicine MK-6024 (efinopegdutide) NASH Neuroscience MK-81894 Schizophrenia SCLC MK-4280A (favezelimab CRC Hematological Malignancies Infectious diseases MK-8591A (doravirine+islatravir)² HIV-1 Infection Vaccines MK-1654 (clesrovimab) Respiratory Syncytial Virus (RSV) Cardiovascular MK-7962 (sotatercept) Pulmonary Arterial Hypertension (EU) Immunology MK-7240 Ulcerative Colitis LAGEVRIO (MK-4482)³ COVID-19 antiviral V116 Pneumococcal vaccine, adult MK-0616 Hypercholesterolemia 31 As of October 26, 2023